January 7, 2014
Kevin Young, Gilead Sciences Executive VP, to Retire
Effective February 4, Kevin Young will retire from Gilead Sciences, The Street reports. As executive vice president of commercial operations, Young was the pharmaceutical company’s top drug salesperson. In his 10 years at Gilead, he oversaw the launch of the HIV drug Truvada and most recently the launch of the hepatitis C drug Sovaldi, which also is approved by the Food and Drug Administration for people who are co-infected with both viruses. His retirement was unexpected by financial analysts.
To read the article, click here.
Search: Kevin Young, Gilead, Truvada, Sovaldi, hepatitis
Scroll down to comment on this story.
[Go to top]